Mektovi

Binimetinib, the active ingredient in Mektovi, is a MEK inhibitor presented as an oral tablet for oral use. It is indicated for adult patients with unresectable or metastatic melanoma that carries a BRAF V600 mutation, helping to limit tumor growth and is administered under specialist supervision.

GNH USA supplies Mektovi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable sourcing for clinical programs across multiple regions.

Mektovi (binimetinib) targets the MAPK pathway in melanoma and is used in BRAF V600‑mutated disease. - Unresectable melanoma with BRAF V600 mutation: provides disease control and improves progression‑free survival. - Metastatic melanoma with BRAF V600 mutation (monotherapy): reduces tumor burden in adult patients. - Metastatic melanoma with BRAF V600 mutation (in combination with encorafenib): enhances overall survival compared with BRAF inhibitor alone.

Binimetinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools that may require supportive care. - Rash: skin redness or irritation, usually mild to moderate. - Nausea: feeling of sickness that may lead to vomiting.

Serious or Rare Side Effects: - Interstitial lung disease: inflammation of lung tissue requiring immediate medical attention. - Retinal disorders: visual disturbances such as serous retinal detachment. - Cardiac dysfunction: decreased left ventricular ejection fraction or heart failure.

When prescribing binimetinib, clinicians should observe several precautionary measures to minimise risks. - Monitor liver function: perform baseline and periodic ALT/AST testing during therapy. - Assess cardiac status: obtain baseline ECG and echocardiogram, repeat as clinically indicated. - Conduct ophthalmologic evaluation: screen for visual changes before treatment and monitor regularly. - Avoid use in severe hepatic impairment: dose adjustment may be required or therapy contraindicated. - Pregnancy and breastfeeding: contraindicated or not recommended due to unknown fetal risk; use effective contraception. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original container.

Binimetinib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce binimetinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase binimetinib plasma levels and toxicity risk. - QT‑prolonging agents (e.g., amiodarone): may heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect oral absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR more frequently as binimetinib may alter anticoagulant effect. - Live vaccines: reduced efficacy; consider timing of vaccination relative to therapy.